I was about to write a post on human papillomavirus (HPV) – related Oropharyngeal Cancer, but recently (Nov 26, 2025) we had an expert talk on the topic at the Hospital. It was by Dr Inmaculada Gallego from Infanta Leonor University Hospital (Madrid), in the context of the Surgical Oncology Update Talks at HLA Moncloa University Hospital. She is founding and board member of the HPV- Madrid Association.
So, what I did is to use AI to make a transcription of the YouTube video-recording of the talk, and then use Perplexity to make an English summary. And of course, review it all before posting.
But if you understand Spanish, you´d better use the YouTube link.
Thank you Dr Inmaculada Gallego. It ended being a remarkable and concise summary of HPV and oropharyngeal Cancer. Here it is.
HPV‑positive oropharyngeal squamous cell carcinoma (OPSCC) is a distinct disease entity with specific epidemiology, biology, clinical behavior and prevention strategies that clearly differ from “classic” tobacco‑ and alcohol‑related Head&Neck Cancer.
What HPV+ OPSCC is
Most oropharyngeal cancers are squamous cell carcinomas arising in the epithelium of the palatine and lingual tonsils, where lymphoid tissue and crypt architecture closely resemble the cervical transformation zone. In developed countries, the incidence is rising almost exponentially, with HPV now accounting for around one‑third of oropharyngeal cancers worldwide and over 60% in some Northern European and US series.
HPV biology and p16
High‑risk HPV genotypes, especially HPV16, drive oncogenesis via the E6 and E7 oncoproteins, which inactivate p53 and pRB, disrupt cell‑cycle control and lead to overexpression of the cellular protein p16. p16 immunohistochemistry on tumor tissue is therefore used as a practical surrogate marker of transcriptionally active HPV, defining p16‑positive versus p16‑negative OPSCC in routine practice.
Unique microenvironment and natural history
HPV‑driven tumors arise mainly in palatine and lingual tonsillar tissue, whose discontinuous basement membrane, deep crypts and rich lymphoid stroma favor both early immune exposure and early, often cystic, nodal metastases from very small primaries. Persistent HPV infection in the oropharynx is surprisingly uncommon compared with cervix, but when it occurs the latency to cancer can exceed 30 years and the aparently proportion of infected patients who eventually develop carcinoma is higher.
Transmission and risk factors
Oral HPV infection is primarily sexually transmitted, most often related to oral sex, but hand‑to‑mouth, mouth‑to‑mouth and vertical transmission at birth are also described; the vast majority of sexually active men and women will encounter HPV during their lifetime. Early sexual debut, higher number of partners, co‑infections (HIV, herpes, chlamydia), specific microbiome profiles and host HLA polymorphisms can facilitate persistent infection and oncogenic transformation.
No shame, no blame. Review FAQs about HPV infection.
Clinical and prognostic differences
HPV‑positive patients are typically 10 years younger than “classic” OPSCC cases, often non‑smokers, and present with small T‑stage primaries but bulky cervical nodes, frequently cystic. Biologically, HPV‑positive tumors lack the high burden of p53/pRB mutations and EGFR overexpression seen in tobacco‑alcohol tumors, respond better to treatment, have fewer distant metastases and second primaries, and show clearly superior survival.
Staging, diagnosis and treatment
The 8th edition TNM introduced a separate staging system for p16‑positive OPSCC and recommends p16 testing in all oropharyngeal tumors and in metastatic neck nodes of unknown primary to focus the search on tonsil and base of tongue and to de‑escalate unnecessary radiation fields. In early stages, surgery (increasingly via transoral robotic surgery, TORS) or radiotherapy are key options, with chemoradiation, complex reconstruction and intensive rehabilitation reserved for advanced tumors in this anatomically and functionally critical region.
Prevention and vaccination
Primary prevention relies on HPV vaccination: in Spain it was incorporated for girls in 2008, extended to younger ages (currently 12 years-old) for maximal pre‑exposure benefit, and more recently (Oct 2022) to boys and defined high‑risk groups in adults. Although it is too early to demonstrate an impact on OPSCC incidence, vaccination has already reduced juvenile laryngeal papillomatosis and persistent cervical infection and precancerous lesions, and there is emerging evidence that high coverage in women has indirectly reduced oral HPV infection in men.
Screening and follow‑up
Unlike cervical cancer, there is currently no validated screening strategy for HPV‑related OPSCC: multiple approaches (salivary HPV DNA, tonsillar swabs, serology, endoscopic techniques, transcervical ultrasound) lack the necessary sensitivity, specificity and positive predictive value for population screening. For treated patients, liquid biopsy (circulating HPV DNA) and serology are promising tools for early detection of recurrence, while routine oral HPV testing in healthy partners or relatives is discouraged due to technical limitations, low predictive value and the risk of unnecessary anxiety.
Key messages for clinical practice
Benign HPV‑related lesions such as papillomas and condylomas are usually caused by low‑risk genotypes and are not precancerous, although they offer an opportunity to recommend vaccination in young patients. Clinicians should reinforce tobacco and alcohol cessation, educate patients about warning signs (persistent oral/oropharyngeal lesions or neck nodes), avoid unvalidated oral HPV screening in asymptomatic individuals, and routinely use each consultation to discuss HPV vaccination as a safe, effective cancer‑preventive intervention.
J Granell (based on I Gallego talk transcript). Dec 9, 2025
One thought on “2025 Update on Human PapillomaVirus – Related Oropharyngeal Cancer”